title: [Cardiovascular calcification inhibitors].
abstract: Vascular calcification is a marker of cardiovascular risk increase. Age and specific disease such as diabetes or chronic kidney disease are important factors for calcification genesis. Vascular calcification process is a complex phenomenon, involving several activators and inhibitors factors. Indeed, recent works related to in vitro and in vivo experimental studies have led to a better understanding of calcification process and identification of molecules able to modulate this system. This revue will summarize some of these molecules with a particular interest of those with therapeutic relevance. We will present: i) calcium sensing receptor and its modulation by cinacalcet; ii) pyrophosphate supplementation; iii) fetuin A and overall propensity serum test for calcification and finally; iv) matrix-Gla-protein and the use of vitamin K to prevent vascular calcification progression.
authors.affiliation: Inserm U1088, UPJV, Amiens, France, Service de pharmacologie, Centre de recherche clinique, CHU Amiens, Amiens, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Liabeuf
authors.affiliation: Université de Liège, Service de néphrologie-dialyse, CHU Sart Tilman, Liège, Belgique.
authors.forename: Pierre
authors.initials: P
authors.lastname: Delanaye
authors.affiliation: Université de Liège, Service de chimie clinique, CHU Sart Tilman, Liège, Belgique.
authors.forename: Étienne
authors.initials: É
authors.lastname: Cavalier
authors.affiliation: Service de pharmacologie, Hôpital européen Georges Pompidou et Inserm U970, Paris, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Guérin
authors.affiliation: Inserm U1088, UPJV, Amiens, France, Laboratoire de biochimie, CHU Amiens, Amiens, France.
authors.forename: Said
authors.initials: S
authors.lastname: Kamel
authors.affiliation: Inserm U1088, UPJV, Amiens, France, Service de néphrologie, Hôpital Ambroise Paré, AP-HP, Université Paris Ile de France Ouest UVSQ, Boulogne/Paris, France.
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Massy
authors.affiliation: Inserm U1088, UPJV, Amiens, France, Service de pharmacologie, Centre de recherche clinique, CHU Amiens, Amiens, France, Université de Liège, Service de néphrologie-dialyse, CHU Sart Tilman, Liège, Belgique, Université de Liège, Service de chimie clinique, CHU Sart Tilman, Liège, Belgique, Service de pharmacologie, Hôpital européen Georges Pompidou et Inserm U970, Paris, France, Laboratoire de biochimie, CHU Amiens, Amiens, France, Service de néphrologie, Hôpital Ambroise Paré, AP-HP, Université Paris Ile de France Ouest UVSQ, Boulogne/Paris, France.
mesh_terms: D002135:Calcium-Binding Proteins / Q000502:physiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D011756:Diphosphates / Q000627:therapeutic use; D016326:Extracellular Matrix Proteins / Q000502:physiology; D006801:Humans; D061205:Vascular Calcification / Q000209:etiology / Q000517:prevention & control*; D060749:alpha-2-HS-Glycoprotein / Q000502:physiology; D000097568:Matrix Gla Protein
chemical_list: D002135:Calcium-Binding Proteins; D011756:Diphosphates; D016326:Extracellular Matrix Proteins; D060749:alpha-2-HS-Glycoprotein; D000097568:Matrix Gla Protein
keywords: calcium sensing receptor; fetuin A; matrix Gla protein; pyrophosphate; vascular calcification